Related Experiment Video
Updated: Jan 30, 2026

Application of Optical Coherence Tomography to a Mouse Model of Retinopathy
Published on: January 12, 2022
Bevacizumab or laser for aggressive posterior retinopathy of prematurity
Michael Blair1,2, Jose Maria Garcia Gonzalez2, Laura Snyder1
1Department of Ophthalmology and Visual Science, University of Chicago, 5841 S. Maryland Avenue, MC2114, Chicago, IL, USA.
Insights
Aggressive posterior retinopathy of prematurity (APROP) often requires retreatment regardless of initial laser or bevacizumab therapy. Bevacizumab treatment resulted in significantly fewer unfavorable structural outcomes compared to laser treatment for AROP.
Area of Science:
- Ophthalmology
- Neonatal care
- Retinal diseases
Background:
- Aggressive posterior retinopathy of prematurity (APROP) is a severe condition affecting premature infants.
- Early detection and treatment are crucial to prevent vision loss.
Purpose of the Study:
- To compare the reactivation rates and structural outcomes of laser versus bevacizumab treatment for APROP.
- To evaluate the long-term efficacy of these treatments in managing APROP.
Main Methods:
- Retrospective chart review of infants diagnosed with APROP.
- Comparison of treatment outcomes between eyes treated with laser photocoagulation and eyes treated with intravitreal bevacizumab.
- Inclusion of fluorescein angiography and prophylactic laser for persistent avascular retina.
Main Results:
- Thirty-six eyes from 19 premature infants were analyzed.
- Unfavorable structural outcomes were significantly lower in the bevacizumab group (1/22 eyes) compared to the laser group (5/14 eyes; P = 0.002).
- Reactivation requiring retreatment was common in both groups (9/22 bevacizumab, 6/14 laser).
Conclusions:
- Reactivation is a common occurrence in APROP, necessitating retreatment irrespective of the initial therapy.
- Initial bevacizumab treatment is associated with significantly better structural outcomes than initial laser treatment for APROP.
Purpose:
The purpose of this study was to report the rate of reactivation and structural outcome, after the laser or bevacizumab treatment for aggressive posterior retinopathy of prematurity (APROP).
Methods:
Retrospective chart review was conducted on consecutive infants with APROP treated with (1) laser or (2) bevacizumab, followed by fluorescein angiography and prophylactic laser to the persistent avascular retina.
Results:
Thirty-six eyes of 19 patients were included in this study. The mean gestational age was 24.5 weeks with a mean birth weight of 632 g in the bevacizumab group and 24.7 weeks and 777 g in the laser group. Unfavorable outcome occurred in 1 of 22 eyes treated with bevacizumab and in 5 of 14 eyes in the laser group (P = 0.002). Reactivation requiring treatment was common in both groups, 9/22 after bevacizumab and 6/14 after laser (ns).
Conclusion:
Regardless of the initial treatment reactivation requiring retreatment is common in eyes with APROP. The unfavorable structural outcome was significantly more common after initial laser treatment than after initial bevacizumab treatment.
Related Concept Videos
Aggression
Secondary Motives: Affiliation Motivation and Aggression Motivation
Cranial Bones: Superior and Posterior View
The frontal bone is the single bone that forms the forehead. At its anterior midline, between the eyebrows, there is a slight depression called the glabella. The frontal bone also forms the supraorbital margin of the orbit. Near the middle of this margin is the supraorbital foramen, the opening that provides passage for a sensory nerve to the forehead. The frontal bone is thickened just above each supraorbital margin,...
Matrix-Assisted Laser Desorption Ionization (MALDI)
Mutations
Fixed Action Patterns

